Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Godamed is an over-the-counter analgesic and antithrombotic medication developed by Dr. Pfleger Arzneimittel. Its primary active ingredient is acetylsalicylic acid (ASA), a small molecule that acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2) enzymes. By inhibiting these enzymes, ASA reduces the synthesis of prostaglandins and thromboxanes, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects. The pain-relief formulation, Godamed 500, is buffered with glycine to improve gastric tolerability. It is indicated for the treatment of mild to moderate pain and fever, as well as for the prevention of cardiovascular events like myocardial infarction and stroke in lower doses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Godamed.